Skip to main content
Top
Published in: Molecular Neurodegeneration 1/2012

Open Access 01-12-2012 | Research article

Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease

Authors: Miriam A Hickey, Chunni Zhu, Vera Medvedeva, Renata P Lerner, Stefano Patassini, Nicholas R Franich, Panchanan Maiti, Sally A Frautschy, Scott Zeitlin, Michael S Levine, Marie-Françoise Chesselet

Published in: Molecular Neurodegeneration | Issue 1/2012

Login to get access

Abstract

Backgound

No disease modifying treatment currently exists for Huntington's disease (HD), a fatal neurodegenerative disorder characterized by the formation of amyloid-like aggregates of the mutated huntingtin protein. Curcumin is a naturally occurring polyphenolic compound with Congo red-like amyloid binding properties and the ability to cross the blood brain barrier. CAG140 mice, a knock-in (KI) mouse model of HD, display abnormal aggregates of mutant huntingtin and striatal transcriptional deficits, as well as early motor, cognitive and affective abnormalities, many months prior to exhibiting spontaneous gait deficits, decreased striatal volume, and neuronal loss. We have examined the ability of life-long dietary curcumin to improve the early pathological phenotype of CAG140 mice.

Results

KI mice fed a curcumin-containing diet since conception showed decreased huntingtin aggregates and increased striatal DARPP-32 and D1 receptor mRNAs, as well as an amelioration of rearing deficits. However, similar to other antioxidants, curcumin impaired rotarod behavior in both WT and KI mice and climbing in WT mice. These behavioral effects were also noted in WT C57Bl/6 J mice exposed to the same curcumin regime as adults. However, neither locomotor function, behavioral despair, muscle strength or food utilization were affected by curcumin in this latter study. The clinical significance of curcumin's impairment of motor performance in mice remains unclear because curcumin has an excellent blood chemistry and adverse event safety profile, even in the elderly and in patients with Alzheimer's disease.

Conclusion

Together with this clinical experience, the improvement in several transgene-dependent parameters by curcumin in our study supports a net beneficial effect of dietary curcumin in HD.
Appendix
Available only for authorised users
Literature
1.
go back to reference The Huntington's Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993, 72: 971-983. 10.1016/0092-8674(93)90585-E.CrossRef The Huntington's Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993, 72: 971-983. 10.1016/0092-8674(93)90585-E.CrossRef
2.
go back to reference Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, et al: Detection of Huntington's disease decades before diagnosis: The Predict HD study. J Neurol Neurosurg Psychiatry. 2008, 79: 874-880. 10.1136/jnnp.2007.128728.PubMedCentralCrossRefPubMed Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, et al: Detection of Huntington's disease decades before diagnosis: The Predict HD study. J Neurol Neurosurg Psychiatry. 2008, 79: 874-880. 10.1136/jnnp.2007.128728.PubMedCentralCrossRefPubMed
3.
go back to reference Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, et al: Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8: 791-801. 10.1016/S1474-4422(09)70170-X.PubMedCentralCrossRefPubMed Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, et al: Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8: 791-801. 10.1016/S1474-4422(09)70170-X.PubMedCentralCrossRefPubMed
4.
go back to reference Aylward EH: Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull. 2007, 72: 152-158. 10.1016/j.brainresbull.2006.10.028.CrossRefPubMed Aylward EH: Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull. 2007, 72: 152-158. 10.1016/j.brainresbull.2006.10.028.CrossRefPubMed
5.
go back to reference Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC: Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007, 62: 1341-1346. 10.1016/j.biopsych.2006.11.034.CrossRefPubMed Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC: Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007, 62: 1341-1346. 10.1016/j.biopsych.2006.11.034.CrossRefPubMed
6.
go back to reference Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SA, Weiler LJ, Cupples LA, Srinidhi J, Gusella JF, Bird ED, Vonsattel JP, Myers RH: Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol. 2001, 49: 29-34. 10.1002/1531-8249(200101)49:1<29::AID-ANA7>3.0.CO;2-B.CrossRefPubMed Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SA, Weiler LJ, Cupples LA, Srinidhi J, Gusella JF, Bird ED, Vonsattel JP, Myers RH: Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol. 2001, 49: 29-34. 10.1002/1531-8249(200101)49:1<29::AID-ANA7>3.0.CO;2-B.CrossRefPubMed
7.
go back to reference Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Juhl A, Pierson RK, Mills J, Langbehn D, et al: Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010, 82: 201-207. 10.1016/j.brainresbull.2010.04.003.PubMedCentralCrossRefPubMed Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Juhl A, Pierson RK, Mills J, Langbehn D, et al: Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010, 82: 201-207. 10.1016/j.brainresbull.2010.04.003.PubMedCentralCrossRefPubMed
8.
go back to reference Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM: Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain. 2008, 131: 1057-1068. 10.1093/brain/awn025.PubMedCentralCrossRefPubMed Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM: Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain. 2008, 131: 1057-1068. 10.1093/brain/awn025.PubMedCentralCrossRefPubMed
9.
go back to reference Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH: Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006, 21: 1317-1325. 10.1002/mds.20979.CrossRefPubMed Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH: Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006, 21: 1317-1325. 10.1002/mds.20979.CrossRefPubMed
10.
go back to reference Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P: Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007, 130: 1759-1766. 10.1093/brain/awm044.CrossRefPubMed Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P: Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007, 130: 1759-1766. 10.1093/brain/awm044.CrossRefPubMed
11.
go back to reference Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, Levine MS, Chesselet MF: Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience. 2008, 157: 280-295. 10.1016/j.neuroscience.2008.08.041.PubMedCentralCrossRefPubMed Hickey MA, Kosmalska A, Enayati J, Cohen R, Zeitlin S, Levine MS, Chesselet MF: Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice. Neuroscience. 2008, 157: 280-295. 10.1016/j.neuroscience.2008.08.041.PubMedCentralCrossRefPubMed
12.
go back to reference Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF: Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol. 2003, 465: 11-26. 10.1002/cne.10776.CrossRefPubMed Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF: Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol. 2003, 465: 11-26. 10.1002/cne.10776.CrossRefPubMed
13.
go back to reference Cummings DM, Cepeda C, Levine MS: Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro. 2010, 2: e00036-PubMedCentralCrossRefPubMed Cummings DM, Cepeda C, Levine MS: Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro. 2010, 2: e00036-PubMedCentralCrossRefPubMed
14.
go back to reference Joshi PR, Wu NP, Andre VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS, Bamford NS: Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci. 2009, 29: 2414-2427. 10.1523/JNEUROSCI.5687-08.2009.PubMedCentralCrossRefPubMed Joshi PR, Wu NP, Andre VM, Cummings DM, Cepeda C, Joyce JA, Carroll JB, Leavitt BR, Hayden MR, Levine MS, Bamford NS: Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci. 2009, 29: 2414-2427. 10.1523/JNEUROSCI.5687-08.2009.PubMedCentralCrossRefPubMed
15.
go back to reference Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, Lynch G: Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci USA. 2009, 106: 4906-4911. 10.1073/pnas.0811228106.PubMedCentralCrossRefPubMed Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, Gall CM, Lynch G: Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci USA. 2009, 106: 4906-4911. 10.1073/pnas.0811228106.PubMedCentralCrossRefPubMed
16.
go back to reference Al-Omar FA, Nagi MN, Abdulgadir MM, Al Joni KS, Al-Majed AA: Immediate and delayed treatments with curcumin prevents forebrain ischemia-induced neuronal damage and oxidative insult in the rat hippocampus. Neurochem Res. 2006, 31: 611-618. 10.1007/s11064-006-9059-1.CrossRefPubMed Al-Omar FA, Nagi MN, Abdulgadir MM, Al Joni KS, Al-Majed AA: Immediate and delayed treatments with curcumin prevents forebrain ischemia-induced neuronal damage and oxidative insult in the rat hippocampus. Neurochem Res. 2006, 31: 611-618. 10.1007/s11064-006-9059-1.CrossRefPubMed
17.
go back to reference Bala K, Tripathy BC, Sharma D: Neuroprotective and anti-ageing effects of curcumin in aged rat brain regions. Biogerontology. 2006, 7: 81-89. 10.1007/s10522-006-6495-x.CrossRefPubMed Bala K, Tripathy BC, Sharma D: Neuroprotective and anti-ageing effects of curcumin in aged rat brain regions. Biogerontology. 2006, 7: 81-89. 10.1007/s10522-006-6495-x.CrossRefPubMed
18.
go back to reference Sharma S, Zhuang Y, Ying Z, Wu A, Gomez-Pinilla F: Dietary curcumin supplementation counteracts reduction in levels of molecules involved in energy homeostasis after brain trauma. Neuroscience. 2009, 161: 1037-1044. 10.1016/j.neuroscience.2009.04.042.PubMedCentralCrossRefPubMed Sharma S, Zhuang Y, Ying Z, Wu A, Gomez-Pinilla F: Dietary curcumin supplementation counteracts reduction in levels of molecules involved in energy homeostasis after brain trauma. Neuroscience. 2009, 161: 1037-1044. 10.1016/j.neuroscience.2009.04.042.PubMedCentralCrossRefPubMed
19.
go back to reference Wu A, Ying Z, Gomez-Pinilla F: Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition. Exp Neurol. 2006, 197: 309-317. 10.1016/j.expneurol.2005.09.004.CrossRefPubMed Wu A, Ying Z, Gomez-Pinilla F: Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition. Exp Neurol. 2006, 197: 309-317. 10.1016/j.expneurol.2005.09.004.CrossRefPubMed
20.
go back to reference Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, et al: Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther. 2008, 326: 196-208. 10.1124/jpet.108.137455.PubMedCentralCrossRefPubMed Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, et al: Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther. 2008, 326: 196-208. 10.1124/jpet.108.137455.PubMedCentralCrossRefPubMed
21.
go back to reference Pan MH, Huang TM, Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999, 27: 486-494.PubMed Pan MH, Huang TM, Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 1999, 27: 486-494.PubMed
22.
go back to reference Yang CS, Sang S, Lambert JD, Lee MJ: Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res. 2008, 52 (Suppl 1): S139-S151.PubMed Yang CS, Sang S, Lambert JD, Lee MJ: Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res. 2008, 52 (Suppl 1): S139-S151.PubMed
23.
go back to reference Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM: Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging. 2001, 22: 993-1005. 10.1016/S0197-4580(01)00300-1.CrossRefPubMed Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM: Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging. 2001, 22: 993-1005. 10.1016/S0197-4580(01)00300-1.CrossRefPubMed
24.
go back to reference Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ: Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem. 2007, 102: 1095-1104. 10.1111/j.1471-4159.2007.04613.x.CrossRefPubMed Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ: Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem. 2007, 102: 1095-1104. 10.1111/j.1471-4159.2007.04613.x.CrossRefPubMed
25.
go back to reference Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001, 21: 8370-8377.PubMed Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001, 21: 8370-8377.PubMed
26.
go back to reference Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM: Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005, 280: 5892-5901.CrossRefPubMed Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM: Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005, 280: 5892-5901.CrossRefPubMed
27.
go back to reference Sanchez I, Mahlke C, Yuan J: Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 2003, 421: 373-379. 10.1038/nature01301.CrossRefPubMed Sanchez I, Mahlke C, Yuan J: Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 2003, 421: 373-379. 10.1038/nature01301.CrossRefPubMed
28.
go back to reference Menalled LB, Zanjani H, MacKenzie L, Koppel A, Carpenter E, Zeitlin S, Chesselet MF: Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol. 2000, 162: 328-342. 10.1006/exnr.1999.7327.CrossRefPubMed Menalled LB, Zanjani H, MacKenzie L, Koppel A, Carpenter E, Zeitlin S, Chesselet MF: Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol. 2000, 162: 328-342. 10.1006/exnr.1999.7327.CrossRefPubMed
29.
go back to reference Maheshwari RK, Singh AK, Gaddipati J, Srimal RC: Multiple biological activities of curcumin: a short review. Life Sci. 2006, 78: 2081-2087. 10.1016/j.lfs.2005.12.007.CrossRefPubMed Maheshwari RK, Singh AK, Gaddipati J, Srimal RC: Multiple biological activities of curcumin: a short review. Life Sci. 2006, 78: 2081-2087. 10.1016/j.lfs.2005.12.007.CrossRefPubMed
30.
go back to reference Baum L, Cheung SK, Mok VC, Lam LC, Leung VP, Hui E, Ng CC, Chow M, Ho PC, Lam S, et al: Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res. 2007, 56: 509-514. 10.1016/j.phrs.2007.09.013.CrossRefPubMed Baum L, Cheung SK, Mok VC, Lam LC, Leung VP, Hui E, Ng CC, Chow M, Ho PC, Lam S, et al: Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res. 2007, 56: 509-514. 10.1016/j.phrs.2007.09.013.CrossRefPubMed
31.
go back to reference Goel A, Kunnumakkara AB, Aggarwal BB: Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. 2008, 75: 787-809. 10.1016/j.bcp.2007.08.016.CrossRefPubMed Goel A, Kunnumakkara AB, Aggarwal BB: Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. 2008, 75: 787-809. 10.1016/j.bcp.2007.08.016.CrossRefPubMed
32.
go back to reference Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME, Frautschy SA: Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging. 2005, 26 (Suppl 1): 133-136.CrossRefPubMed Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME, Frautschy SA: Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging. 2005, 26 (Suppl 1): 133-136.CrossRefPubMed
33.
go back to reference Moncada S, Bolanos JP: Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem. 2006, 97: 1676-1689. 10.1111/j.1471-4159.2006.03988.x.CrossRefPubMed Moncada S, Bolanos JP: Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem. 2006, 97: 1676-1689. 10.1111/j.1471-4159.2006.03988.x.CrossRefPubMed
34.
go back to reference Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J. 2008, 22: 659-661.CrossRefPubMed Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J. 2008, 22: 659-661.CrossRefPubMed
35.
go back to reference Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, et al: Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008, 28: 110-113. 10.1097/jcp.0b013e318160862c.CrossRefPubMed Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, et al: Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008, 28: 110-113. 10.1097/jcp.0b013e318160862c.CrossRefPubMed
36.
go back to reference Jang JY, Park D, Shin S, Jeon JH, Choi BI, Joo SS, Hwang SY, Nahm SS, Kim YB: Antiteratogenic effect of resveratrol in mice exposed in utero to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Eur J Pharmacol. 2008, 591: 280-283. 10.1016/j.ejphar.2008.05.033.CrossRefPubMed Jang JY, Park D, Shin S, Jeon JH, Choi BI, Joo SS, Hwang SY, Nahm SS, Kim YB: Antiteratogenic effect of resveratrol in mice exposed in utero to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Eur J Pharmacol. 2008, 591: 280-283. 10.1016/j.ejphar.2008.05.033.CrossRefPubMed
37.
go back to reference Skibola CF, Smith MT: Potential health impacts of excessive flavonoid intake. Free Radic Biol Med. 2000, 29: 375-383. 10.1016/S0891-5849(00)00304-X.CrossRefPubMed Skibola CF, Smith MT: Potential health impacts of excessive flavonoid intake. Free Radic Biol Med. 2000, 29: 375-383. 10.1016/S0891-5849(00)00304-X.CrossRefPubMed
38.
go back to reference Bhavanishankar T, Murthy V: Reproductive response of rats fed turmeric (Curcuma longa L) and its alcoholic extract. J Food Sci Technol. 1987, 24: 45-49. Bhavanishankar T, Murthy V: Reproductive response of rats fed turmeric (Curcuma longa L) and its alcoholic extract. J Food Sci Technol. 1987, 24: 45-49.
39.
go back to reference Ganiger S, Malleshappa HN, Krishnappa H, Rajashekhar G, Ramakrishna Rao V, Sullivan F: A two generation reproductive toxicity study with curcumin, turmeric yellow, in Wistar rats. Food Chem Toxicol. 2007, 45: 64-69. 10.1016/j.fct.2006.07.016.CrossRefPubMed Ganiger S, Malleshappa HN, Krishnappa H, Rajashekhar G, Ramakrishna Rao V, Sullivan F: A two generation reproductive toxicity study with curcumin, turmeric yellow, in Wistar rats. Food Chem Toxicol. 2007, 45: 64-69. 10.1016/j.fct.2006.07.016.CrossRefPubMed
40.
go back to reference Phan J, Hickey MA, Zhang P, Chesselet MF, Reue K: Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum Mol Genet. 2009, 18: 1006-1016. 10.1093/hmg/ddn428.PubMedCentralCrossRefPubMed Phan J, Hickey MA, Zhang P, Chesselet MF, Reue K: Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum Mol Genet. 2009, 18: 1006-1016. 10.1093/hmg/ddn428.PubMedCentralCrossRefPubMed
41.
go back to reference Dikshit P, Goswami A, Mishra A, Nukina N, Jana NR: Curcumin enhances the polyglutamine-expanded truncated N-terminal huntingtin-induced cell death by promoting proteasomal malfunction. Biochem Biophys Res Commun. 2006, 342: 1323-1328. 10.1016/j.bbrc.2006.02.104.CrossRefPubMed Dikshit P, Goswami A, Mishra A, Nukina N, Jana NR: Curcumin enhances the polyglutamine-expanded truncated N-terminal huntingtin-induced cell death by promoting proteasomal malfunction. Biochem Biophys Res Commun. 2006, 342: 1323-1328. 10.1016/j.bbrc.2006.02.104.CrossRefPubMed
42.
go back to reference Aiken CT, Tobin AJ, Schweitzer ES: A cell-based screen for drugs to treat Huntington's disease. Neurobiol Dis. 2004, 16: 546-555. 10.1016/j.nbd.2004.04.001.CrossRefPubMed Aiken CT, Tobin AJ, Schweitzer ES: A cell-based screen for drugs to treat Huntington's disease. Neurobiol Dis. 2004, 16: 546-555. 10.1016/j.nbd.2004.04.001.CrossRefPubMed
43.
go back to reference Jana NR, Dikshit P, Goswami A, Nukina N: Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem. 2004, 279: 11680-11685. 10.1074/jbc.M310369200.CrossRefPubMed Jana NR, Dikshit P, Goswami A, Nukina N: Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem. 2004, 279: 11680-11685. 10.1074/jbc.M310369200.CrossRefPubMed
44.
go back to reference Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ: Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet. 2001, 10: 137-144. 10.1093/hmg/10.2.137.CrossRefPubMed Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ: Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet. 2001, 10: 137-144. 10.1093/hmg/10.2.137.CrossRefPubMed
45.
go back to reference Menalled LB, Chesselet MF: Mouse models of Huntington's disease. Trends Pharmacol Sci. 2002, 23: 32-39. 10.1016/S0165-6147(00)01884-8.CrossRefPubMed Menalled LB, Chesselet MF: Mouse models of Huntington's disease. Trends Pharmacol Sci. 2002, 23: 32-39. 10.1016/S0165-6147(00)01884-8.CrossRefPubMed
46.
go back to reference Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, Li SH, Yi H, Vonsattel JP, Gusella JF, et al: Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet. 2000, 9: 503-513. 10.1093/hmg/9.4.503.CrossRefPubMed Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, Li SH, Yi H, Vonsattel JP, Gusella JF, et al: Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet. 2000, 9: 503-513. 10.1093/hmg/9.4.503.CrossRefPubMed
47.
go back to reference Paxinos G, Franklin KBJ: The Mouse Brain in Stereotaxic Coordinates. 2001, Florida: Academic, 2 Paxinos G, Franklin KBJ: The Mouse Brain in Stereotaxic Coordinates. 2001, Florida: Academic, 2
49.
go back to reference Hickey MA, Franich NR, Medvedeva V, Chesselet MF: Mouse models of mental illness and neurological disease: Huntington's disease. The Mouse Nervous System. Edited by: Watson C, Paxinos G, Puelles L. 2011, London: Elsevier, 3: 752-765. 2 Hickey MA, Franich NR, Medvedeva V, Chesselet MF: Mouse models of mental illness and neurological disease: Huntington's disease. The Mouse Nervous System. Edited by: Watson C, Paxinos G, Puelles L. 2011, London: Elsevier, 3: 752-765. 2
50.
go back to reference Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, Head SR, Sutcliffe JG, Thomas EA: Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem. 2006, 96: 743-757. 10.1111/j.1471-4159.2005.03588.x.CrossRefPubMed Desplats PA, Kass KE, Gilmartin T, Stanwood GD, Woodward EL, Head SR, Sutcliffe JG, Thomas EA: Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem. 2006, 96: 743-757. 10.1111/j.1471-4159.2005.03588.x.CrossRefPubMed
51.
go back to reference Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD, Regulier E, Delorenzi M, Tabrizi SJ, Luthi-Carter R: Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci USA. 2007, 104: 14424-14429. 10.1073/pnas.0703652104.PubMedCentralCrossRefPubMed Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD, Regulier E, Delorenzi M, Tabrizi SJ, Luthi-Carter R: Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci USA. 2007, 104: 14424-14429. 10.1073/pnas.0703652104.PubMedCentralCrossRefPubMed
52.
go back to reference Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, et al: The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA. 2008, 105: 15564-15569. 10.1073/pnas.0804249105.PubMedCentralCrossRefPubMed Thomas EA, Coppola G, Desplats PA, Tang B, Soragni E, Burnett R, Gao F, Fitzgerald KM, Borok JF, Herman D, et al: The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA. 2008, 105: 15564-15569. 10.1073/pnas.0804249105.PubMedCentralCrossRefPubMed
53.
go back to reference Benn CL, Fox H, Bates G: Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. BMC Molecular Neurodegeneration. 2008, 3: 1-17. 10.1186/1750-1326-3-1.CrossRef Benn CL, Fox H, Bates G: Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. BMC Molecular Neurodegeneration. 2008, 3: 1-17. 10.1186/1750-1326-3-1.CrossRef
54.
55.
go back to reference Kennedy L, Evans E, Chen CM, Craven L, Detloff PJ, Ennis M, Shelbourne PF: Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet. 2003, 12: 3359-3367. 10.1093/hmg/ddg352.CrossRefPubMed Kennedy L, Evans E, Chen CM, Craven L, Detloff PJ, Ennis M, Shelbourne PF: Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet. 2003, 12: 3359-3367. 10.1093/hmg/ddg352.CrossRefPubMed
56.
go back to reference Hickey MA, Zhu C, Medvedeva V, Franich NR, Levine MS, Chesselet MF: Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease. Mol Cell Neurosci. 2012, 49: 149-157. 10.1016/j.mcn.2011.10.007.PubMedCentralCrossRefPubMed Hickey MA, Zhu C, Medvedeva V, Franich NR, Levine MS, Chesselet MF: Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease. Mol Cell Neurosci. 2012, 49: 149-157. 10.1016/j.mcn.2011.10.007.PubMedCentralCrossRefPubMed
57.
go back to reference Schilling G, Savonenko AV, Coonfield ML, Morton JL, Vorovich E, Gale A, Neslon C, Chan N, Eaton M, Fromholt D, et al: Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol. 2004, 187: 137-149. 10.1016/j.expneurol.2004.01.003.CrossRefPubMed Schilling G, Savonenko AV, Coonfield ML, Morton JL, Vorovich E, Gale A, Neslon C, Chan N, Eaton M, Fromholt D, et al: Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol. 2004, 187: 137-149. 10.1016/j.expneurol.2004.01.003.CrossRefPubMed
58.
go back to reference Mohorko N, Repovs G, Popovic M, Kovacs GG, Bresjanac M: Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. J Neuropathol Exp Neurol. 2010, 69: 405-414. 10.1097/NEN.0b013e3181d709eb.CrossRefPubMed Mohorko N, Repovs G, Popovic M, Kovacs GG, Bresjanac M: Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples. J Neuropathol Exp Neurol. 2010, 69: 405-414. 10.1097/NEN.0b013e3181d709eb.CrossRefPubMed
59.
go back to reference Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, et al: Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001, 61: 1058-1064.PubMed Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, et al: Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001, 61: 1058-1064.PubMed
60.
go back to reference Barry J, Fritz M, Brender JR, Smith PE, Lee DK, Ramamoorthy A: Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin. J Am Chem Soc. 2009, 131: 4490-4498. 10.1021/ja809217u.PubMedCentralCrossRefPubMed Barry J, Fritz M, Brender JR, Smith PE, Lee DK, Ramamoorthy A: Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin. J Am Chem Soc. 2009, 131: 4490-4498. 10.1021/ja809217u.PubMedCentralCrossRefPubMed
61.
go back to reference Kunwar A, Sandur SK, Krishna M, Priyadarsini KI: Curcumin mediates time and concentration dependent regulation of redox homeostasis leading to cytotoxicity in macrophage cells. Eur J Pharmacol. 2009, 611: 8-16. 10.1016/j.ejphar.2009.03.060.CrossRefPubMed Kunwar A, Sandur SK, Krishna M, Priyadarsini KI: Curcumin mediates time and concentration dependent regulation of redox homeostasis leading to cytotoxicity in macrophage cells. Eur J Pharmacol. 2009, 611: 8-16. 10.1016/j.ejphar.2009.03.060.CrossRefPubMed
62.
go back to reference Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S: Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004, 431: 805-810. 10.1038/nature02998.CrossRefPubMed Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S: Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004, 431: 805-810. 10.1038/nature02998.CrossRefPubMed
63.
go back to reference Saudou F, Finkbeiner S, Devys D, Greenberg ME: Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998, 95: 55-66. 10.1016/S0092-8674(00)81782-1.CrossRefPubMed Saudou F, Finkbeiner S, Devys D, Greenberg ME: Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998, 95: 55-66. 10.1016/S0092-8674(00)81782-1.CrossRefPubMed
64.
go back to reference Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, Finkbeiner S: Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular Pathogenesis. J Neurosci. 2010, 30: 10541-10550. 10.1523/JNEUROSCI.0146-10.2010.PubMedCentralCrossRefPubMed Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, Finkbeiner S: Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular Pathogenesis. J Neurosci. 2010, 30: 10541-10550. 10.1523/JNEUROSCI.0146-10.2010.PubMedCentralCrossRefPubMed
65.
go back to reference Gong B, Lim MC, Wanderer J, Wyttenbach A, Morton AJ: Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res Bull. 2008, 75: 146-157. 10.1016/j.brainresbull.2007.08.005.CrossRefPubMed Gong B, Lim MC, Wanderer J, Wyttenbach A, Morton AJ: Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res Bull. 2008, 75: 146-157. 10.1016/j.brainresbull.2007.08.005.CrossRefPubMed
66.
go back to reference Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A: Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One. 2009, 4: e5727-10.1371/journal.pone.0005727.PubMedCentralCrossRefPubMed Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A: Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One. 2009, 4: e5727-10.1371/journal.pone.0005727.PubMedCentralCrossRefPubMed
67.
go back to reference Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB: Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA. 1998, 95: 6480-6485. 10.1073/pnas.95.11.6480.PubMedCentralCrossRefPubMed Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB: Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA. 1998, 95: 6480-6485. 10.1073/pnas.95.11.6480.PubMedCentralCrossRefPubMed
68.
go back to reference Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P: DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004, 44: 269-296. 10.1146/annurev.pharmtox.44.101802.121415.CrossRefPubMed Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P: DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004, 44: 269-296. 10.1146/annurev.pharmtox.44.101802.121415.CrossRefPubMed
69.
go back to reference Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, et al: Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain. 2011, 134: 119-136. 10.1093/brain/awq278.CrossRefPubMed Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, et al: Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain. 2011, 134: 119-136. 10.1093/brain/awq278.CrossRefPubMed
70.
go back to reference Park KS, Eun JS, Kim HC, Moon DC, Hong JT, Oh KW: (-)-Epigallocatethin-3-O-gallate counteracts caffeine-induced hyperactivity: evidence of dopaminergic blockade. Behav Pharmacol. 2010, 21: 572-575. 10.1097/FBP.0b013e32833beffb.CrossRefPubMed Park KS, Eun JS, Kim HC, Moon DC, Hong JT, Oh KW: (-)-Epigallocatethin-3-O-gallate counteracts caffeine-induced hyperactivity: evidence of dopaminergic blockade. Behav Pharmacol. 2010, 21: 572-575. 10.1097/FBP.0b013e32833beffb.CrossRefPubMed
71.
go back to reference Underwood BR, Imarisio S, Fleming A, Rose C, Krishna G, Heard P, Quick M, Korolchuk VI, Renna M, Sarkar S, et al: Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. Hum Mol Genet. 2010, 19: 3413-3429. 10.1093/hmg/ddq253.PubMedCentralCrossRefPubMed Underwood BR, Imarisio S, Fleming A, Rose C, Krishna G, Heard P, Quick M, Korolchuk VI, Renna M, Sarkar S, et al: Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. Hum Mol Genet. 2010, 19: 3413-3429. 10.1093/hmg/ddq253.PubMedCentralCrossRefPubMed
72.
go back to reference Shults CW, Flint Beal M, Song D, Fontaine D: Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol. 2004, 188: 491-494. 10.1016/j.expneurol.2004.05.003.CrossRefPubMed Shults CW, Flint Beal M, Song D, Fontaine D: Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol. 2004, 188: 491-494. 10.1016/j.expneurol.2004.05.003.CrossRefPubMed
73.
go back to reference Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, et al: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002, 59: 1541-1550. 10.1001/archneur.59.10.1541.CrossRefPubMed Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, et al: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002, 59: 1541-1550. 10.1001/archneur.59.10.1541.CrossRefPubMed
74.
go back to reference Menalled LB, Sison JDYW, Olivieri M, Li X-J, Li H, Zeitlin S, Chesslet M-F: Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci. 2002, 22: 8266-8276.PubMed Menalled LB, Sison JDYW, Olivieri M, Li X-J, Li H, Zeitlin S, Chesslet M-F: Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J Neurosci. 2002, 22: 8266-8276.PubMed
75.
go back to reference Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, et al: Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006, 15: 965-977. 10.1093/hmg/ddl013.CrossRefPubMed Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, et al: Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006, 15: 965-977. 10.1093/hmg/ddl013.CrossRefPubMed
76.
go back to reference Hickey MA, Gallant K, Gross GG, Levine MS, Chesselet MF: Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis. 2005, 20: 1-11. 10.1016/j.nbd.2005.01.024.CrossRefPubMed Hickey MA, Gallant K, Gross GG, Levine MS, Chesselet MF: Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis. 2005, 20: 1-11. 10.1016/j.nbd.2005.01.024.CrossRefPubMed
77.
go back to reference Porsolt RD, Le Pichon M, Jalfre M: Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977, 266: 730-732. 10.1038/266730a0.CrossRefPubMed Porsolt RD, Le Pichon M, Jalfre M: Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977, 266: 730-732. 10.1038/266730a0.CrossRefPubMed
78.
go back to reference Steru L, Chermat R, Thierry B, Simon P: The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985, 85: 367-370. 10.1007/BF00428203.CrossRef Steru L, Chermat R, Thierry B, Simon P: The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985, 85: 367-370. 10.1007/BF00428203.CrossRef
79.
go back to reference Cryan JF, Mombereau C, Vassout A: The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005, 29: 571-625. 10.1016/j.neubiorev.2005.03.009.CrossRefPubMed Cryan JF, Mombereau C, Vassout A: The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005, 29: 571-625. 10.1016/j.neubiorev.2005.03.009.CrossRefPubMed
Metadata
Title
Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease
Authors
Miriam A Hickey
Chunni Zhu
Vera Medvedeva
Renata P Lerner
Stefano Patassini
Nicholas R Franich
Panchanan Maiti
Sally A Frautschy
Scott Zeitlin
Michael S Levine
Marie-Françoise Chesselet
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2012
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-7-12

Other articles of this Issue 1/2012

Molecular Neurodegeneration 1/2012 Go to the issue